Glenmark Pharma To Launch Potassium Phosphates Injection In March 2026

Glenmark’s presence in the injectable therapeutics segment.
Glenmark Pharma, a global pharmaceutical company, continues to expand its product portfolio with the introduction of Potassium Phosphates Injection USP. This move underscores its commitment to addressing critical medical needs and supporting hospitals and clinics with reliable treatment options.

Product Launch And Distribution
The distribution of Potassium Phosphates Injection USP will commence in March 2026. Glenmark will offer the product in multiple vial sizes, catering to diverse clinical requirements and ensuring flexibility for healthcare practitioners.

Clinical Significance
Potassium Phosphates Injection USP plays a vital role in replenishing electrolytes and supporting patient care in hospital settings. By introducing this product, Glenmark aims to strengthen its injectable solutions portfolio and meet growing demand in critical care.

Key Highlights

• Distribution begins March 2026
• Available in multiple vial sizes
• Supports electrolyte replenishment in clinical care
• Expands Glenmark’s injectable therapeutics portfolio
• Enhances accessibility for hospitals and healthcare providers

Sources: Business news announcement, company filings